Inuvo Reports Record Fourth Quarter 2024 Revenue of $26.2 Million, 26% Year-Over-Year Growth and Net Income

Stock Information for Asterias Biotherapeutics Inc. Common Series A

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Asterias Biotherapeutics Inc. Common Series A

Inuvo to Present at the LD Micro Main Event XIX
Inuvo Appoints Rob Buchner as Chief Operating Officer to Accelerate Growth of IntentKey
Inuvo to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8th-10th
Inuvo Posts 25% Growth in the Second Quarter 2025
Inuvo to Host Second Quarter 2025 Financial Results Conference Call on Thursday, August 7th at 4:15 P.M. ET
Inuvo to Participate in the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2025 on June 24-25, 2025
Inuvo Reaffirms 25% Q2 YOY Growth Guidance and Completes 1:10 Reverse Stock Split
Inuvo to Present at Ladenburg Thalmann Technology Innovation Expo on May 21

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.